Moderna's cancer vaccine may be a 'major breakthrough', scientists say

A phase two clinical trial found the shot combined with immunotherapy drug Merck slashed the risk of melanoma returning by 44 percent compared to using the drug alone.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news